BD Appoints Michael Feld EVP and President of the Life Sciences Segment

BD named Michael Feld as executive vice president and president of the Life Sciences segment for BD, effective Aug. 20, 2024, and he will serve as a member of the Executive Leadership Team. He succeeds Dave Hickey, who retired from BD last month after 10 years with the company.
 
Tom Polen, chairman, CEO, and president of BD commented: “Mike’s expertise in applying commercial and operational excellence principles to deliver impactful results, coupled with his experience in diagnostic solutions, position him well to lead our Life Sciences segment. As we build momentum behind our BD Excellence operating system, Mike’s continuous improvement mindset will be an asset to BD as our Life Sciences team continues to drive efficiencies and meaningfully expand value for our customers, their patients, and the global healthcare ecosystem.”
 
Feld joins BD from Veralto, a spin-off of Danaher, where he was most recently president of Hach, a global leader in water quality products. Before that, Feld held several senior roles at Danaher and served as president of several other Danaher businesses including Mammotome, XOS, and Dover Motion.
 
As president of the BD Life Sciences segment, which includes Biosciences, Diagnostics Solutions, and Specimen Management, Feld will be responsible for the organization that develops advancements from discovery to diagnosis. Under his leadership, BD Life Sciences will continue to focus on developing solutions around smart, connected, end-to-end workflows, specimen collection, and diagnostics in new care settings, which will improve the diagnosis and treatment of chronic conditions.